NHS Greater Manchester has been advised to review a £42 million dermatology contract award after regulators found it to be in breach of procurement rules. This development brings renewed focus onto how major NHS commissioning bodies manage high-value contracts and comply with complex public procurement law.
The contract was for community dermatology services and was awarded following a competitive process. However, the regulatory oversight indicated that aspects of the procurement did not fully align with the Provider Selection Regime (PSR), the framework governing NHS health service contracts. The ICB has been instructed to review the award for compliance and transparency.
Sources confirm that procedural failings were identified by regulators, deemed significant enough to justify reconsideration of the original decision. Under the PSR, commissioners are mandated to act transparently, fairly, and proportionately, and must ensure all bidders have an equal chance to participate and challenge the outcome.
Past procurement reviews have flagged issues such as incomplete documentation of evaluation criteria, unclear scoring justifications, and failures to re-start formal standstill periods following procedural changes. Such breaches, procurement specialists warn, can undermine a tender’s fairness and call into question whether the award represents true value and competition.
The advisory note suggests the ICB needs a closer examination of the process, not just to avert legal challenges but also to maintain confidence among suppliers and local stakeholders. The review may result in the re-evaluation of submissions or potentially the re-running of the tender if substantial regulatory non-compliance is confirmed.
The scale of this multi-year dermatology contract, valued at around £42 million, is significant as these services are crucial for supporting community access, improving outpatient pathways, and reducing pressure on secondary care, particularly given the national lengthening of NHS waiting lists for skin conditions and workforce constraints.
Given the contract's importance, compliance is paramount. Commissioners must carefully balance clinical need, cost-effectiveness, and legal fairness in a market with limited specialist providers and rising demand.
The ICB has acknowledged the recommendation and is preparing a formal action plan. This is expected to involve a detailed review of the procurement process, potential consultation with independent legal and procurement experts, and clear communication with bidders.
Should the review determine a material flaw in the procurement, the ICB could face requirements to re-run the tender, modify evaluation scores, or publish a revised contract notice under the PSR. Any such action would delay service delivery and have budgetary implications for the commissioning body. This incident occurs while many ICBs are managing financial pressures, leadership changes, and organisational shifts as they finalise contracts for 2026/27, all while adapting to and ensuring adherence to the new Provider Selection Regime and evolving procurement guidance.
For the health and technology sector, this case underscores the vital need for rigorous procurement governance and comprehensive documentation. Digital platforms that facilitate audit trails, compliance reporting, and tender evaluation can assist commissioning organisations in meeting regulatory standards and defending their decisions.
Ultimately, the situation highlights the inherent tension between the NHS's urgent need to secure high-quality services and the legal and procedural safeguards that protect competition and fairness. Commissioners must strike this balance to prevent costly delays and preserve trust among service users and suppliers alike. Stakeholders will be monitoring the ICB’s review closely to see if it triggers a broader discussion about procurement training, oversight, and the practical implementation of the Provider Selection Regime across NHS commissioning bodies in England.
